Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Sep 17, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Aug 11, 2026Notice of sale · Form 144Cambrian BioPharma Inc · 10% Stockholder · $3.6MOpen the filing ↗
- Aug 4, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year226
SEC filings on record42417 flagged findings
Reported transactions (Form 4)80since Jun 11, 2024 · and 15 other holdings
Corporate events (8-K)30since Dec 8, 2022
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
Identity
Formerly traded as SNSE (until Jun 16, 26).
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-06-18share offering or dilution eventrecentOpen filing ↗“…offering, investors who purchase our common stock in this offering will suffer dilution in their investment. In addition, we have a…”
+1 more passage from the same document
- “…common stock in this offering will suffer dilution in their investment. In addition, we have a significant number of stock options…”
- 2026-06-18capital return (buybacks/dividends)recentOpen filing ↗“…liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary…”
+1 more passage from the same document
- “…sales agreement prospectus immediately follows the base prospectus. Table of Contents PROSPECTUS Common Stock Preferred Stock Debt…”
- 2026-06-18merger or acquisition eventrecentOpen filing ↗“…listed on The Nasdaq Capital Market under the symbol “FTH”. We were originally incorporated as Panacea Pharmaceuticals, Inc., or…”
- 2026-06-10share offering or dilution eventrecentOpen filing ↗“…for accounting purposes. Concurrently with the Acquisition, we entered into a Securities Purchase Agreement (the “Purchase…”
+1 more passage from the same document
- “…shares of Common Stock pursuant to the Certificate of Designation, at an aggregate purchase price of approximately $200…”
- 2026-06-10capital return (buybacks/dividends)recentOpen filing ↗“…liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary…”
- 2026-06-10merger or acquisition eventrecentOpen filing ↗“…CD39), and SNS-201, a bispecific antibody designed to conditionally activate CD28 through monovalent CD28 engagement and bivalent…”
+1 more passage from the same document
- “…antibody designed to conditionally activate CD28 through monovalent CD28 engagement and bivalent pH-selective VISTA binding, which…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
Reverse splits in 5 years
1 reverse split in 5 years (1:20 on Jun 17, 2025) · 1:20 cumulative
The other times: of 818 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 382 lost more than half and 209 rose (809 with a price a year later).
Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.
The 25 most recent filings (of 424)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Sep 17, 268-K ↗Current report · A senior executive left or was appointed
- Sep 15, 26Form 4 ↗Insider transaction
- Sep 15, 26Form 3 ↗Insider transaction
- Aug 14, 26SCHEDULE 13G/A ↗Passive stake · Caligan Partners LP · 2.4% · event on Jun 30, 26 · amendment
- Aug 14, 26SCHEDULE 13G/A ↗Passive stake · Trails Edge Capital Partners, LP · 2.0% · event on Jun 30, 26 · amendment
- Aug 14, 26SCHEDULE 13G ↗Passive stake · VK Services, LLC · 10.2% · event on Jun 15, 26
- Aug 14, 26SCHEDULE 13G/A ↗Passive stake · amendment
- Aug 11, 26Form 144 ↗Notice of proposed sale
- Aug 4, 268-K ↗Current report · Results
- Aug 4, 2610-Q ↗Quarterly report
- Jul 28, 26Form 3 ↗Insider transaction
- Jul 23, 268-K ↗Current report · A senior executive left or was appointed
- Jun 23, 26Form 3 ↗Insider transaction
- Jun 23, 26SCHEDULE 13G ↗Passive stake · S2G Investments, LLC · 10.0% · event on Jun 15, 26
- Jun 23, 26SCHEDULE 13G ↗Passive stake · Suvretta Capital Management, LLC · 7.8% · event on Jun 15, 26
- Jun 18, 268-K ↗Current report · Entered a material agreement
- Jun 18, 26S-3ASR ↗Securities offering
- Jun 16, 26Form 4 ↗Insider transaction
- Jun 16, 26Form 3 ↗Insider transaction
424 filings on record, the oldest from Dec 9, 20.
Listing the 25 most recent filings of the 424 on record.
5921
- Sep 17, 26A senior executive left or was appointed8-K 5.02 ↗
- Jul 23, 26A senior executive left or was appointed8-K 5.02 ↗
- Jun 18, 26Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Jun 15, 26A material agreement was terminated+5 more in the same filing8-K 1.02 ↗
- Jun 10, 26A senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
- Apr 16, 26A senior executive left or was appointed8-K 5.02 ↗
- Feb 18, 26Completed an acquisition or disposal+6 more in the same filing8-K 2.01 ↗
- Feb 13, 26A senior executive left or was appointed8-K 5.02 ↗
- Dec 23, 25A senior executive left or was appointed8-K 5.02 ↗
- Jul 9, 25Listing notice (8-K 3.01)8-K 3.01 ↗
- Jan 7, 25Listing notice (8-K 3.01)+1 more in the same filing8-K 3.01 ↗
- Oct 30, 24A senior executive left or was appointed8-K 5.02 ↗
13 older filings not shown · The record reaches back to Apr 5, 21.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Jul 12, 24Listing notice (8-K 3.01)8-K 3.01 ↗
- Oct 20, 23Listing notice (8-K 3.01)8-K 3.01 ↗
- Dec 8, 22Restructuring plan with committed costs+3 more in the same filing8-K 2.05 ↗
The full record holds 5 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- VK Services, LLC10.2%Jun 15, 26SCHEDULE 13G ↗6 co-filers on this document — the figure is the largest single stake, not their sum.
- S2G Investments, LLC10.0%Jun 15, 26SCHEDULE 13G ↗
- StemPoint Capital LP9.9%Mar 31, 26SCHEDULE 13G ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
- Millennium Management LLC9.6%Feb 24, 26SCHEDULE 13G ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
- Suvretta Capital Management, LLC7.8%Jun 15, 26SCHEDULE 13G ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
show 3 more holdershide
- ICS Opportunities II LLC3.1%Jun 1, 26SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
- Caligan Partners LP2.4%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- Trails Edge Capital Partners, LP2.0%Jun 30, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Aug 11, Cambrian BioPharma Inc filed notice of intent to sell up to $3.6M. That is about 9.71% of shares outstanding.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
No sale of theirs is on record yet in Form 4; the 90-day window is still open.
- Jul 1, 26Buy$103KBRIAN C STEPHENSONChief Financial Officer↗
- Jul 1, 26Buy$15KBRIAN C STEPHENSONChief Financial Officer↗
- Jun 30, 26Buy$44KBRIAN C STEPHENSONChief Financial Officer↗
- Jun 30, 26Buy$39KBRIAN C STEPHENSONChief Financial Officer↗
- Jun 30, 26Buy$106KBRIAN C STEPHENSONChief Financial Officer↗
- Jun 29, 26Buy$19KBRIAN C STEPHENSONChief Financial Officer↗
- Jun 26, 26Buy$14KBRIAN C STEPHENSONChief Financial Officer↗
- Jun 26, 26Buy$105KBRIAN C STEPHENSONChief Financial Officer↗
- Jun 26, 26Buy$35KBRIAN C STEPHENSONChief Financial Officer↗
- Jun 26, 26Buy$3KBRIAN C STEPHENSONChief Financial Officer↗
- Jun 24, 26Buy$73KBRIAN C STEPHENSONChief Financial Officer↗
- Jun 24, 26Buy$78KBRIAN C STEPHENSONChief Financial Officer↗
There are 24 more transactions in this stretch.
Stock compensation, tax and giftsshow the 4 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
The full record holds 128 transactions and goes back to Jun 10, 22.
Its sector and its market
Faeth Therapeutics, Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Faeth Therapeutics, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Faeth Therapeutics, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- Series with incidents in the period; the chart shows what could be kept.
- SEC records
- 424 documents on file, from Dec 9, 2020 to Sep 17, 2026.
- Company description
- No description available.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.